Basem directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers. He is a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc. He was on three papers published in The New England Journal of Medicine (prostate cancer, chronic neutrophilic leukemia, lung cancer) and two in Lancet (Shingles vaccine and head and neck cancer). Basem is board certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.
Basem's training background includes:
MD: Mayo Clinic
Ph.D. in Biochemistry: Mayo Clinic
MBA: University of North Carolina, Chapel Hill
Internal Medicine Residency: George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship: Stanford
Biochemistry Post-Doctoral Fellowship: Stanford
MIT Xpro Course Certificate: Designing Artificial Intelligence Products MIT Xpro: Course Certificate: Robotics Essentials
MIT Xpro: Course Certificate: Drug and Medical Device Development
MIT Professional Education Course Certificate: Applied Data Science Bootcamp
Basem resisted the trend towards subspecialization in his career as he feels ideation often happens at the level of the forest, not the trees. He believes many of the greatest future innovations will be at the interface of various disciplines. His area of clinical expertise is precision medicine, and his ability to treat patients in all hematology/medical oncology disciplines uniquely positions me to sequence molecular-based therapies in the context of conventional therapy and clinical trials.
Basem presently is:
CEO and Founder of CancerClarity (presently in stealth mode)
CEO and Founder of CancerLight (presently in stealth mode)
CEO and Co-Founder of Revolution Cancer Medical Care PLLC
National medical director for 2 phase 1 Xbiotech clinical trials
Pharmaceutical consultant to several companies
Full-time hematologist/medical oncologist
Contributing author for biopharmatrend.com ("The Insider's Guide to Translational Medicine")
Author of the "Cancer Patients Don't Have an Expiration Date" series
Advisor to several companies in different disciplines
Basem recently turned down several high-visibility positions to pursue his vision. His goal in life has always been to help people. As a physician, he helped people on an individual basis every day. However, he became dissatisfied as his singular focus now is to help as many people in the shortest time frame possible.
Basem created the Revolution Cancer International Molecular Tumor Board (RCIMTB) to change the way molecular tumor boards are conducted. He hopes the tumor board will epitomize translational medicine as it resides at the interface of drug development, patient care, AI/ML, clinical trials, and precision medicine.
Dr. Janakiraman Subramanian is the Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI). He also serves as the Director for ISCI Data and Analytics Research Core and
leads the thoracic oncology research program at ISCI. He is institutional principal investigator for several prospective clinical trials in thoracic oncology. He is a member of the steering group
for the American Society of Clinical Oncology QOPI Certification Program. He completed his residency in Internal Medicine at Saint Lukes Hospital in Saint Louis and fellowship in Hematology&Oncology at Washington University School of Medicine in Saint Louis, Missouri.
Silambarasan completed his Bachelor of Science in Genetics at Ayya Nadar Janaki Ammal College and his Masters of Science in biomedical sciences at the University of Madras. He obtained his Ph.D. in genetics, molecular biology, and biochemistry at the National University of Singapore (NUS). He finished his postdoctoral fellowship in genomics at NUS. Silambarasan holds certificates in medical affairs, clinical/medical laboratory science/research and allied professions, pharmacovigilance and clinical research from Duke-NUS and Clinicminds, respectively. He completed the ACMG Human/Medical Genetics and Genomics Certificate Course.
Silambarasan is a clinical genomicist with 10 years of hands-on experience in genetic testing, including Karyotyping, FISH, chromosomal microarray, Next-Generation Seq (NGS) - (Illumina - HiSeq and NovaSeq Series). He was head of genetic affairs for Bione, and is presently a personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.
Copyright © 2022 Revolution Cancer International Molecular Tumor Board - All Rights Reserved.
Powered by GoDaddy